TRCT
CRVO icon

Tower Research Capital (TRC)’s CervoMed CRVO Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.74K Sell
2,173
-5
-0.2% -$18 ﹤0.01% 4184
2026
Q1 		$8.58K Buy
2,178
+1,646
+309% +$8.6K ﹤0.01% 3962
2025
Q4 		$4.2K Sell
532
-798
-60% -$6.41K ﹤0.01% 4244
2025
Q3 		$10.8K Sell
1,330
-983
-42% -$8.43K ﹤0.01% 3958
2025
Q2 		$14.5K Sell
2,313
-5,696
-71% -$48.5K ﹤0.01% 3833
2025
Q1 		$73.3K Buy
8,009
+5,555
+226% +$21.2K ﹤0.01% 1957
2024
Q4 		$5.74K Buy
2,454
+1,897
+341% +$18.4K ﹤0.01% 4249
2024
Q3 		$8.13K Buy
+557
New +$8.63K ﹤0.01% 3983
2024
Q1 		– Sell
-725
Closed -$5.53K – 5891
2023
Q4 		$5.53K Buy
725
+429
+145% +$3.71K ﹤0.01% 4830
2023
Q3 		$1.37K Sell
296
-1,311
-82% -$6.61K ﹤0.01% 5348
2023
Q2 		$8.05K Sell
1,607
-606
-27% -$3.52K ﹤0.01% 4480
2023
Q1 		$14K Buy
2,213
+341
+18% +$3.02K ﹤0.01% 3872
2022
Q4 		$14K Buy
1,872
+540
+41% +$4.5K ﹤0.01% 3496
2022
Q3 		$11K Buy
1,332
+1,169
+717% +$11.9K ﹤0.01% 4428
2022
Q2 		$2K Buy
163
+162
+16,200% +$2.01K ﹤0.01% 5520
2022
Q1 		$0 Buy
+1
New +$20 ﹤0.01% 6140
2021
Q4 		– Sell
-135
Closed -$5K – 6188
2021
Q3 		$5K Buy
+135
New +$5.62K ﹤0.01% 4838
2021
Q2 		– Sell
-77
Closed -$5K – 5520
2021
Q1 		$5K Buy
+77
New +$6.46K ﹤0.01% 4654
2017
Q1 		– Hold
0
– -$1K – 3171
2016
Q4 		– Hold
0
– – – 3585

Other funds holding CRVO

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Tower Research Capital (TRC)'s CRVO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its CervoMed (CRVO) stake by 0.23% in Q2 2026, selling an estimated $18 and leaving 2,173 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4184.

Tower Research Capital (TRC) first reported a position in CRVO in Q1 2021 and has held it in 18 quarters since. The position peaked at $73.3K in Q1 2025. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.

  • Tower Research Capital (TRC) held 2,173 shares of CervoMed worth $6.74K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5 CervoMed shares in Q2 2026, an estimated $18.
  • CervoMed made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4184 holding.
  • Tower Research Capital (TRC) first reported a position in CervoMed in Q1 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s CervoMed position peaked at $73.3K in Q1 2025.
  • 37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.